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Background: To explore long-term effects of agalsidase alfa on Fabry disease cardiomyopathy in adults.
Methods: Retrospective analysis of prospectively collected data at a single center in Mainz, Germany, revealed that
45 adult patients (21 men, 24 women) had received agalsidase alfa for approximately 10 years. Data were extracted
for cardiac and heart failure status, echocardiographic evaluations of cardiac structure and function, and renal function
at treatment start and during agalsidase alfa treatment.
Results: After 10 years of agalsidase alfa treatment, heart failure classification had improved by at least 1 class in 22/42
patients, and angina scores were stable or improved in 41/42 patients. During treatment, no patients without left
ventricular hypertrophy (LVH) at treatment initiation developed LVH, and no patients with LVH at treatment initiation
showed a decline in left ventricular mass.
Conclusions: Approximately 10 years of agalsidase alfa treatment appeared to have beneficial effects for controlling
progression and improving some symptoms of Fabry-associated cardiomyopathy.
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Lysosomal storage disorderBackground
Fabry disease is a rare, inherited, X-chromosome linked
glycosphingolipid storage disorder (OMIM 301500). In
Fabry disease, mutations in the α-galactosidase A (GLA)
gene cause functional deficiency of the enzyme α-GLA.
In affected patients, lack of α-GLA activity leads to pro-
gressive accumulation of glycosphingolipids, particularly
globotriaosylceramide (Gb3), in lysosomes, affecting
almost all tissues and organs. By adulthood, patients with
Fabry disease may experience a range of serious complica-
tions, such as cardiomyopathy, that result in significant
morbidity and reduced life expectancy [1–10]. Because
the GLA gene is located on the X-chromosome, males
generally tend to be more severely affected than females,
as the latter retain a physiologically significant level of* Correspondence: kampmann@mail.uni-mainz.de
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fore, generally occurs later in life, with cardiomyopathy
the most common and serious sign [9].
Cardiac changes in Fabry disease include progressive,
infiltrative hypertrophic cardiomyopathy characterized
by predominantly left ventricular (LV) wall thickening
without cavity dilatation, structural changes in the mitral
and aortic valves, and conduction abnormalities that may
lead to increased susceptibility to arrhythmias [7–15]. The
severity of cardiac symptoms correlates with overall dis-
ease progression over time, with intracellular deposition
of Gb3 and fibrosis thought to be major, but not the only,
mechanisms underlying these abnormalities [7, 8, 16–18].
Agalsidase alfa enzyme replacement therapy (ERT) for
Fabry disease has been available for more than 10 years
[19–23]. A number of studies of different designs sup-
port the efficacy and effectiveness of ERT, including
agalsidase alfa, with regard to cardiac outcomes in adults
[13, 21–27]. Reports of other studies, however, have sug-
gested that ERT with either agalsidase alfa or beta may berticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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and more severe symptoms at ERT initiation or that find-
ings are equivocal [28–30].
To establish a clear understanding of the long-term
effectiveness of agalsidase alfa in preventing and control-
ling the progression of cardiomyopathy in Fabry disease,
we conducted a 10-year retrospective medical record
review-based evaluation of morphological and functional
cardiac changes in adult men and women treated with
agalsidase alfa.
Methods
Study design and patients
A single-center retrospective analysis was carried out
using prospectively collected data extracted from the
medical records of patients with Fabry disease who were
under the care of the University Children’s Hospital in
Mainz, Germany, which is a participating center in the
Fabry Outcome Survey (sponsored by Shire). Predefined
data were extracted from medical records after written
consent from patients and after local institutional review
board and ethical committee approval of this analysis.
Eligible patients had a Fabry disease diagnosis confirmed
by enzyme assay (males) and/or DNA analysis (males
and females), were aged ≥ 14 years at treatment start, and
had received agalsidase alfa (Replagal®; Shire, Lexington,
Massachusetts, USA) ERT for approximately 10 years.
All eligible patients received ERT continuously and none
had ERT withdrawn or stopped. Female patients with inter-
mittent reimbursement from the health care system were
excluded from this analysis and 4 female patients were
excluded because ERT was stopped for more than a year.
Outcomes analyzed
Demographic characteristics and disease-related clinical
parameters at the start of treatment were collected. Data
were extracted for cardiac and heart failure status, echo-
cardiographic evaluations of cardiac structure and func-
tion, and renal function at treatment start and then at
predefined time points during agalsidase alfa treatment.
Heart failure and angina were evaluated as New York
Heart Association (NYHA) classification of heart failure
and Canadian Cardiovascular Society (CCS) grading of
angina pectoris scores, respectively [30–32]. Detailed
echocardiography was performed using digital echocar-
diographic equipment with appropriate transducers.
Mean values were taken from instantaneous measure-
ments made over 3 cardiac cycles from M-mode tracings
according to American Society of Echocardiography
recommendations [33]. Systolic and diastolic structural
and functional parameters were calculated as described
elsewhere [9, 14, 34]. LV mean wall thickness (MWT)
measurements of ≥16 mm were considered to indicate se-
vere LV hypertrophy (LVH) [35]. LV mass was calculatedfrom echocardiographic measurement data and values
indexed to patient height (LV mass index [LVMI]) [36].
Values of >50 g/m2.7 were considered indicative of LVH
[35]. Systolic function was evaluated from LV ejection
fraction (LVEF) measured using two-dimensional echocar-
diography [7, 9, 14, 37].
Renal function was evaluated from serum creatinine;
estimated glomerular filtration rate (eGFR), calculated as
eGFR Modification of Diet in Renal Disease values; [38]
and time-averaged urinary protein excretion.
Data analyses
Descriptive statistics were calculated for all values. Changes
from baseline in study parameters were evaluated as
changes in least squares (LS) mean values over time with
95 % confidence intervals (CI) adjusted for baseline demo-
graphic variables, or by calculating t statistic values. Differ-
ences were considered statically significant if p - values
were ≤0.05. SAS/STAT® software version 9.2 (SAS Institute
Inc., Cary, North Carolina, USA) was used for statistical
analyses.
Results
Forty-five patients (21 males, 24 females) met the criteria
for inclusion in this analysis. Patients had been treated for
a median (range) of 10.8 (9.6–12.5) years between January
2001 and December 2013. The mean (standard deviation
[SD]) age at start of ERT was 38.7 (14.1) years for females
and 30.2 (9.5) years for males. Mean blood pressure values
and heart rates were within normal ranges (Table 1). One
female and 2 male patients received pacemakers and 1
other male patient developed conduction abnormalities.
Mean body mass index values were within healthy ranges
at baseline (Table 1) but increased slightly over 10 years
(LS mean [SD] change from baseline, males 1.74 [0.42]
kg/m2; females 2.79 [0.48] kg/m2; both p < 0.0001). Virtu-
ally no residual enzyme activity was observed before treat-
ment in male patients (median [range] 0.08 [0.00–0.14]
units; n = 17), whereas female patients had activity indica-
tive of heterozygosity (0.66 [0.35–1.09] units; n = 15). As
previously described [25], the female patients all had signs
or symptoms typical of Fabry disease (eg, neuropathic
pain, gastrointestinal involvement, stroke, proteinuria,
decreased renal function, and/or LVH) and had their
Fabry diagnosis confirmed by mutation analysis.
Concomitant therapies included: percutaneous translu-
minal coronary angioplasty in 2 patients; placement of a
dual chamber pacemaker in 3 patients; dialysis in 1 pa-
tient who had progressed to end-stage renal disease; and
beta-adrenergic blocking agents in 1 patient. In addition,
all patients initiated therapy with angiotensin-converting
enzyme inhibitors during the first 5 years of ERT. No
patients received cardiac resynchronization therapy or
an automatic implantable cardioverter defibrillator.
Table 1 Demographic and basic clinical parameters at treatment start
Baseline parameter Females Males Overall
N (%) 24 (53.3) 21 (46.7) 45
Age, mean (SD), years 38.6 (14.2) 30.2 (9.5) 34.7 (12.8)
Age at ERT start, mean (SD), years 38.7 (14.1) 30.2 (9.5) 34.7 (12.8)
Age at ERT start, median (range), years 37.2 (15.6–61.4) 31.4 (14.9–44.9) 34.5 (14.9–61.4)
BMI, mean (SD), kg/m2 23.5 (3.6) 21.6 (3.5) 22.6 (3.6)
Systolic BP, mean (SD), mmHg 127.3 (13.2) 126.2 (16.0) 126.8 (14.4)
Diastolic BP, mean (SD), mmHg 72.3 (9.1) 68.2 (10.3) 70.4 (9.8)
Heart rate, mean (SD), bpm 64.0 (13.1) 65.1 (7.7) 64.5 (10.8)
Diabetes, n (%) 0 (0) 0 (0) 0 (0)
Current smoker, n (%) 2 (8.3) 3 (14.3) 5 (11.1)
Arterial hypertension, n (%) 2 (8.3) 3 (14.3) 5 (11.1)
BMI: body mass index; bpm: beats per minute; BP: blood pressure; ERT: enzyme replacement therapy; SD: standard deviation
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At treatment start, heart failure symptoms (NYHA
class ≥ II) were present in 31 % and anginal symptoms
(CCS score ≥ 2) were present in 24 % of patients (Fig. 1).
After 10 years of agalsidase alfa treatment, NYHA classi-
fication had improved by at least 1 class in 22/42
patients. Classifications were unchanged in 19 patients;
only 1 patient had a worse classification, and no patients
were classified as NYHA class III, compared with 9
before treatment (Fig. 1). Fifteen of 42 patients had an






























Fig. 1 a Cluster analysis of NYHA heart failure classification. b Cluster analysis o
10 years of agalsidase alfa enzyme replacement therapy. Values in the boxes ind
indicate directions of changes in classifications or scores, and numbers adjacent
Cardiovascular Society; NYHA: New York Heart Association10 years of ERT, with only 1 patient showing deterior-
ation, and none having scores of 2, 3, or 4, compared
with 11 patients before ERT (Fig. 1).
Cardiac structural evaluations
Before ERT, mean (SD) MWT values for males (12.3
[2.9] mm; n = 21) and females (11.7 [2.5] mm; n = 24)
indicated mild hypertrophy, although values ranged from
normal to some instances of severe LVH (range, males
8.2–18.0 mm; females 8.7–17.0 mm). After 10 years of




































f CCS grading of angina pectoris scores before and after approximately
icate the numbers (and percentages) of patients in that category. Arrows
to arrows show the number of patients with that change. CCS: Canadian
Kampmann et al. Orphanet Journal of Rare Diseases  (2015) 10:125 Page 4 of 7mean [95 % CI] change −1.89 [−2.58, −1.19] mm; p <
0.0001), with changes apparent after 1 year (−2.08
[−2.69, −1.46] mm; p < 0.0001). Statistically significant
changes were also apparent after 1 year in females
(LS mean [95 % CI] change −2.01 [−2.55, −1.47] mm;
p < 0.0001), although after 10 years, MWT was not
significantly different from before treatment (−0.48
[−1.05, 0.09] mm; p = 0.0999).
At start of treatment, LVMI values suggested a varying
degree of LVH, with 71 % (n = 15/21) of men and 67 %
(n = 16/24) of women having LVMI ≥50 g/m2.7. After
10 years of ERT, LVMI was not significantly changed
in patents with baseline LVMI <50 g/m2.7; however,
in males with baseline values ≥50 g/m2.7, LVMI was
significantly reduced after 10 years (LS mean [95 %
CI] change −13.55 [−23.05, −4.06] g/m2.7; p = 0.0061;
Fig. 2). A marked improvement was apparent in these pa-
tients after just 1 year (LS mean [95 % CI] change −16.46
[−23.81, −9.11] g/m2.7; p < 0.0001). A similar improvement
after 1 year was observed in females with LVH and
sustained for 3 years (1 year LS mean [95 % CI]
change −16.69 [−23.62, −9.75] g/m2.7; p < 0.0001), al-
though after 10 years, mean LVMI was found not to
be significantly different from baseline (Fig. 2).
Cardiac functional evaluations
Mean LVEF values before treatment were ≥60 % in all
patients and were largely unchanged after 10 years of
ERT in male patients (Table 2). In female patients, a sta-
tistically significant, albeit very slight, reduction in LVEFFig. 2 Left ventricular mass indexed to height during 10 years’ agalsidase alfa
or ≥50 g/m2.7 before treatment. Data points are means with standard deviatio
change from baseline among males with LVMI ≥50 g/m2.7 before treatment.
with LVMI ≥50 g/m2.7 before treatment. ‡Statistically significant (p < 0.05) cha
before treatmentwas observed; however, mean LVEF was still within the
normal range. Mean (SD) heart rates remained similar
to baseline after 10 years (males 67.4 [20.0] bpm; females
64.7 [11.7] bpm).
Renal function
Among patients (8 males, 5 females) with pretreatment
eGFR ≥90 mL/min/1.73 m2, the mean annual decline in
eGFR over 10 years was not statistically significant. In
patients with poorer renal function (10 males, 11 females),
eGFR seemed to improve in the first 3 years of ERT
(Fig. 3). After 10 years, however, eGFR values were not
significantly changed regardless of renal function before
ERT. Serum creatinine values (baseline mean [SD] males
1.0 [0.2] mg/dL; n = 19; females 0.9 [0.2] mg/dL; n = 16)
were also not significantly different after 10 years of ERT.
Time-adjusted urinary protein levels did not change sig-
nificantly over 10 years in male (mean [SD] 112.5 [35.8]
mg/24 h; n = 8) and female patients (115.3 [48.0] mg/
24 h; n = 6) without pre-treatment proteinuria (i.e.
urine protein <200 mg/24 h at baseline), and in females
with proteinuria (507.6 [388.9] mg/24 h; n = 7) at ERT ini-
tiation. However, in the 10 male patients who had protein-
uria before treatment, urinary protein was significantly
increased (baseline mean [SD] 659.0 [889.0] mg/24 h; 10-
year change 297.0 [376.7] mg/24 h; p = 0.0342).
Discussion
This study represents one of the largest and longest-term
evaluations to date of the progression of cardiomyopathytreatment for male and female patients stratified by LVMI <50 g/m2.7
ns. LVMI: left ventricular mass index. *Statistically significant (p < 0.05)
†Statistically significant (p < 0.05) change from baseline among females
nge from baseline among females with LVMI <50 g/m2.7
Table 2 Changes in left ventricular ejection fraction functional




Baseline, mean (SD) 71.9 (7.6), n = 23 69.9 (7.3), n = 21
10-year n, mean (SD) 68.4 (6.9) 69.8 (7.0)
Change from baselinea −3.64 (−6.74, −0.54) 1.31 (−2.16, 4.78)
p = 0.022 p =0.4546
aAdjusted changes from baseline: LS mean (95 % CI) changes
CI: confidence interval; LS: least squares; SD: standard deviation
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agalsidase alfa ERT.
The progression of untreated Fabry disease differs in
some respects in men and women as a result of differences
in levels of residual enzyme activity [3, 39–42]. Additionally,
the differential cardiac effects in men and women may be
caused by a mosaic distribution of affected and unaffected
cardiac myocytes in women [2, 43]. Although symptoms
appear approximately 10 years earlier in males, cardiac in-
volvement is now understood to be prevalent in adult pa-
tients of both genders [2, 9, 15], with reports of ≥90 % of
patients being affected by cardiomyopathy, with LVH in
about half of untreated men and one third of untreated
women, and >50 % of female patients reporting chest pain
[13, 39–41]. The severity of cardiac abnormalities increases
with age and, alongside renal disease, are a significant cause
of morbidity and early mortality in both genders [2, 3, 7–


























Fig. 3 eGFR during 10 years’ agalsidase alfa treatment in male and female pa
Data points are means with standard deviations. eGFR: glomerular filtration ra
with eGFR <90 mL/min/1.73 m2 before treatment. †Statistically significant (p <
1.73 m2 before treatmentwomen (mean [SD] age, 47.0 [17.9] years) found that 25
(69 %) had LVH at baseline; after 4 years of agalsidase alfa
ERT, there was significant reduction in LVMI in 22/25
(88 %) patients who had LVH at baseline, with 7/25 (28 %)
no longer classified as having LVH [25]. Further, among
those women with LVMI classified as normal at baseline,
only 1 had progressed to LVH after 4 years of ERT [25].
One of the goals for ERT should be the prevention
of future organ damage in patients who are not yet
severely affected at the time of diagnosis, but who
may develop symptoms later in their lives without
treatment. It should also be noted that some patients
will not develop progressive symptoms even without
treatment and thus will have little or no benefit from
treatment. The patient cohort presented here consists
of classical Fabry patients with typical signs and
symptoms of Fabry disease who still show excellent
responses to treatment. However, despite the benefi-
cial effects of ERT in patients with Fabry disease, pa-
tients in advanced stages of the disease may still die.
From an analysis of deceased patients of our overall
center cohort who have not been included in the ana-
lysis presented here due to their shorter treatment
time (data not shown), no obvious overall demo-
graphic or Fabry disease-related differences were
noted between those patients who died during the ob-
servation period and our patient cohort in total, ex-
cept for the fact that more deceased patients were
male and older at treatment initiation. Therefore,
these non-responders may have been primarily those
patients in whom ERT was initiated too late.5 6 7 8 9 10
of treatment
Males < 90 mL/min/1.732
Females < 90 mL/min/1.732
Males  90 mL/min/1.732
Females  90 mL/min/1.732
†
tients stratified by eGFR <90 or ≥90 mL/min/1.73 m2 before treatment.
te. *Statistically significant (p < 0.05) change from baseline among males
0.05) change from baseline among females with eGFR <90 mL/min/
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disease who had received agalsidase alfa for approximately
10 years. Improvements in NYHA heart failure classifica-
tion and CCS angina scores were observed over this period.
From a structural perspective, early improvements in
MWT in male and female patients were observed, although
there were no significant differences at 10 years. Also,
LVMI values in the normal range before treatment were
maintained over 10 years in men and women. Where LVH
was present before ERT, improvements were apparent after
just 1 year, with benefits in male patients sustained after
10 years and with deterioration controlled in females.
Cardiac functionality parameters were stable over the
10-year study period, as evidenced by maintenance of
LVEF values within the normal range. Electrocardiographic
data are not presented because they do not reflect limited
changes in LV mass and typically do not detect changes
seen during ERT. Renal function was also generally
maintained after 10 years of ERT. While differences
are apparent in some of the 10-year analysis results
between men and women, possibly because of the more
severe effects of Fabry disease in men, we found that dis-
ease progression was generally attenuated and symptoms
of cardiomyopathy were stable or improved in male and
female patients who received 10 years of ERT.
A number of studies and analyses have explored the ef-
fects of agalsidase alfa on cardiomyopathy in Fabry disease
over shorter time frames. Over treatment duration periods
from 6 months to 5 years, agalsidase alfa has been re-
ported to delay the onset of cardiac involvement, to re-
duce or stabilize LVMI in men and women with Fabry
disease, and to reduce myocardial Gb3 in males [21–26].
Specifically, in patients with signs of LVH before ERT, de-
creases in LVMI over 1 to 5 years of treatment have been
reported, whereas in patients without initial LVH, 3 to
5 years of treatment prevented progression [21, 23,
24]. Functionally, increased or stabilized mid-wall frac-
tional shortening after 5 years of treatment regardless of
baseline LVH has been reported [21], with no LVEF
changes found in male patients after 6 months’ treatment
in another study [22]. The findings of our retrospective
analysis are thus in accord with those of previous studies
of treatment over shorter time periods and further indi-
cate the potential benefits of agalsidase alfa. Our results
suggest that agalsidase alfa has long-term benefits for
Fabry disease cardiomyopathy regardless of gender and of
the severity of cardiac symptoms before treatment.
Limitations
This was a retrospective analysis of data from medical
records and not a prospective randomized controlled
trial. Hence, patients were not randomly selected to re-
ceive ERT and the analysis did not include a comparator
(control) group of untreated patients. Comparisons withpre-treatment data were therefore used to evaluate
changes in parameters. As these baseline data were col-
lected 10 years previously, the treated patients may have
been considerably older when the comparisons were
made, and aging itself may have had an adverse impact
on the symptoms evaluated. Although M-mode echocar-
diography has inherent limitations of variability and
reproducibility, and thus is not the ideal method for serial
measurement of LVMI, it is widely available and com-
monly used. Finally, patients whose data were included
had been referred for specialist treatment and, in the case
of the female patients, severe disease was more likely.
Conclusions
In this 10-year evaluation of adult men and women with
Fabry disease who received agalsidase alfa treatment,
there was no progression of cardiomyopathy as determined
by a range of structural and functional parameters.
Abbreviations
LVH: Left ventricular hypertrophy; LV: Left ventricular; ERT: Enzyme
replacement therapy; NYHA: New York Heart Association; CCS: Canadian
Cardiovascular Society; MWT: Mean wall thickness; LVEF: LV ejection fraction;
eGFR: estimated glomerular filtration rate; LS: Least squares; LVMI: Left
ventricular mass index.
Competing interests
CK has served on advisory committees for BioMarin and Shire; has participated in
clinical studies sponsored by Actelion, BioMarin, Genzyme, Gore, and Shire; has
received research support from BioMarin and Shire; and has received consulting/
speaker fees from BioMarin, Gore, and Shire. MB has received honoraria, travel
support, and unrestricted grants from BioMarin, Genzyme, Shire, and Synageva. AP
is an employee of Shire. This analysis was funded by Shire.
Authors’ contributions
CK and MB made substantial contributions to the design, acquisition, and
interpretation of the data; and were involved in drafting and critically
revising the manuscript for important intellectual content. AP conducted the
statistical analysis of the data and made substantial contributions to the
interpretation of the data; and was involved in critically revising the
manuscript for important intellectual content. CK, AP, and MB all gave final
approval of the version to be published and agreed to be accountable for all
aspects of the work in ensuring that questions related to the accuracy or
integrity of any part of the work are appropriately investigated and resolved.
All authors read and approved the final manuscript.
Acknowledgments
We thank all patients who consented to the inclusion of their clinical data in
this analysis. We also would like to thank Dr. Nesrin Karabul, Dr. Leila Arash-Kaps,
Dr. Catharina Whybra, Dr. Eugen Mengel, Dr. J. Reinke, and the whole team of
the Villa Metabolica for their help and support. Medical writing assistance during
the preparation of this manuscript, supported financially by Shire, was provided
by Annie Rowe and Margit Rezabek of Excel Scientific Solutions.
Statement of authorship
The authors take responsibility for all aspects of the reliability and freedom
from bias of the data presented and their discussed interpretation.
Author details
1Section Head for Congenital Heart Defects, Center for Pediatric and
Adolescent Medicine, University Medical Center, University of Mainz,
Langenbeckstr. 1, Mainz DE-55101, Germany. 2Statistical Programmer, Rare
Diseases Business Unit, Global Outcomes Research, Shire, Zug, Switzerland.
3Professor Emeritus, Department of Pediatrics, University Medical Center,
University of Mainz, Mainz, Germany.
Kampmann et al. Orphanet Journal of Rare Diseases  (2015) 10:125 Page 7 of 7Received: 4 May 2015 Accepted: 6 September 2015References
1. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, et al. Natural course
of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome
Survey. J Med Genet. 2009;46(8):548–52.
2. Kampmann C, Linhart A, Baehner F, Palecek T, Wiethoff CM, Miebach E, et al.
Onset and progression of the Anderson-Fabry disease related cardiomyopathy.
Int J Cardiol. 2008;130(3):367–73.
3. Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S,
et al. Fabry disease: progression of nephropathy, and prevalence of cardiac
and cerebrovascular events before enzyme replacement therapy. Nephrol
Dial Transplant. 2009;24(7):2102–11.
4. Sadick N, Thomas L. Cardiovascular manifestations in Fabry disease: a clinical
and echocardiographic study. Heart Lung Circ. 2007;16(3):200–6.
5. Weidemann F, Breunig F, Beer M, Sandstede J, Stork S, Voelker W, et al. The
variation of morphological and functional cardiac manifestation in Fabry
disease: potential implications for the time course of the disease. Eur Heart
J. 2005;26(12):1221–7.
6. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A,
Kampmann C, et al. Fabry disease defined: baseline clinical
manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin
Invest. 2004;34(3):236–42.
7. Kampmann C, Baehner F, Ries M, Beck M. Cardiac involvement in Anderson-
Fabry disease. J Am Soc Nephrol. 2002;13 Suppl 2:S147–9.
8. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudová J, Karetová D, et al. New
insights in cardiac structural changes in patients with Fabry's disease. Am
Heart J. 2000;139(6):1101–8.
9. Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M, et al.
Cardiac manifestations of Anderson-Fabry disease in heterozygous females.
J Am Coll Cardiol. 2002;40(9):1668–74.
10. Perrot A, Osterziel KJ, Beck M, Dietz R, Kampmann C. Fabry disease: focus on
cardiac manifestations and molecular mechanisms. Herz. 2002;27(7):699–702.
11. Linhart A. The heart in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann
G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford
PharmaGenesis; 2006. p. 189–201.
12. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other
lysosomal storage disorders. Heart. 2007;93(4):528–35.
13. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta
A, et al. Cardiac manifestations of Anderson-Fabry disease: results from the
international Fabry outcome survey. Eur Heart J. 2007;28(10):1228–35.
14. Kampmann C, Wiethoff CM, Martin C, Wenzel A, Kampmann R, Whybra C,
et al. Electrocardiographic signs of hypertrophy in Fabry disease-associated
hypertrophic cardiomyopathy. Acta Paediatr Suppl. 2002;91 Suppl 439:21–7.
15. Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, et al. Prevalence
and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.
Am J Cardiol. 2005;96(6):842–6.
16. Elleder M, Bradová V, Smíd F, Budĕsínský M, Harzer K, Kustermann-Kuhn B, et al.
Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease.
Report on a case simulating hypertrophic non-obstructive cardiomyopathy.
Virchows Arch A Pathol Anat Histopathol. 1990;417(5):449–55.
17. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, et al. An
atypical variant of Fabry's disease with manifestations confined to the myocardium.
N Engl J Med. 1991;324(6):395–9.
18. Costanzo L, Buccheri S, Capranzano P, Di Pino L, Curatolo G, Rodolico M,
et al. Early cardiovascular remodelling in Fabry disease. J Inherit Metab Dis.
2014;37(1):109–16.
19. Schiffmann R, Kopp JB, Austin 3rd HA, Sabnis S, Moore DF, Weibel T, et al.
Enzyme replacement therapy in Fabry disease: a randomized controlled
trial. JAMA. 2001;285(21):2743–9.
20. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical benefit of
enzyme replacement therapy in Fabry disease. Kidney Int. 2006;69(7):1216–21.
21. Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, et al.
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's
disease: an analysis of registry data. Lancet. 2009;374(9706):1986–96.
22. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, et al.
Effects of enzyme replacement therapy on the cardiomyopathy of
Anderson-Fabry disease: a randomised, double-blind, placebo-controlled
clinical trial of agalsidase alfa. Heart. 2008;94(2):153–8.23. Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, et al.
Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest.
2004;34(12):838–44.
24. Kampmann C, Linhart A, Devereux RB, Schiffmann R. Effect of agalsidase alfa
replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a
12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
Clin Ther. 2009;31(9):1966–76.
25. Whybra C, Miebach E, Mengel E, Gal A, Baron K, Beck M, et al. A 4-year
study of the efficacy and tolerability of enzyme replacement therapy with
agalsidase alfa in 36 women with Fabry disease. Genet Med. 2009;11(6):441–9.
26. Zamorano J, Serra V, Peréz de Isla L, Feltes G, Calli A, Barbado FJ, et al. Usefulness of
tissue Doppler on early detection of cardiac disease in Fabry patients and potential
role of enzyme replacement therapy (ERT) for avoiding progression of disease. Eur
J Echocardiogr. 2011;12(9):671–7.
27. Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CE. Natural course of
Fabry disease and the effectiveness of enzyme replacement therapy: a systematic
review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit
Metab Dis. 2014;37(3):341–52.
28. El Dib RP, Nascimento P, Pastores GM. Enzyme replacement therapy for
Anderson-Fabry disease. Cochrane Database Syst Rev. 2013;2(Feb 28), CD006663.
29. Weidemann F, Niemann M, Störk S, Breunig F, Beer M, Sommer C, et al. Long-
term outcome of enzyme-replacement therapy in advanced Fabry disease:
evidence for disease progression towards serious complications. J Intern Med.
2013;274(4):331–41.
30. Weidemann F, Strotmann JM, Niemann M, Herrmann S, Wilke M, Beer M,
et al. Heart valve involvement in Fabry cardiomyopathy. Ultrasound Med
Biol. 2009;35(5):730–5.
31. American Heart Assocation. Classification of functional capacity and objective
assessment. http://my.americanheart.org/professional/StatementsGuidelines/
ByPublicationDate/PreviousYears/Classification-of-Functional-Capacity-and-
Objective-Assessment_UCM_423811_Article.jsp. Accessed 14 Apr 2015.
32. Campeau L. The Canadian Cardiovascular Society grading of angina pectoris
revisited 30 years later. Can J Cardiol. 2002;18(4):371–9.
33. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding
quantitation in M-mode echocardiography: results of a survey of
echocardiographic measurements. Circulation. 1978;58(6):1072–83.
34. Kampmann C, Wiethoff CM, Wenzel A, Stolz G, Betancor M, Wippermann CF,
et al. Normal values of M mode echocardiographic measurements of more than
2000 healthy infants and children in central Europe. Heart. 2000;83(6):667–72.
35. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al.
Recommendations for chamber quantification. Eur J Echocardiogr.
2006;7(2):79–108.
36. Devereux RB, Koren MJ, de Simone G, Roman MJ, Laragh JH. Left ventricular
mass as a measure of preclinical hypertensive disease. Am J Hypertens.
1992;5(6 Pt 2):S175–81.
37. Dumesnil JG, Shoucri RM, Laurenceau JL, Turcot J. A mathematical model of
the dynamic geometry of the intact left ventricle and its application to
clinical data. Circulation. 1979;59(5):1024–34.
38. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic
kidney disease: evaluation, classification, and stratification. Am J Kidney Dis.
2002;39(2 Suppl 1):S1–266.
39. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical
manifestations and impact of disease in a cohort of 60 obligate carrier
females. J Med Genet. 2001;38(11):769–75.
40. MacDermot KD, Holmes A, Miners AH. Natural history of Fabry disease in
affected males and obligate carrier females. J Inherit Metab Dis. 2001;24
Suppl 2:13–4. discussion 1–2.
41. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical
manifestations and impact of disease in a cohort of 98 hemizygous males. J Med
Genet. 2001;38(11):750–60.
42. Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M.
Cardiac manifestations of Anderson-Fabry disease in children and
adolescents. Acta Paediatr. 2008;97(4):463–9.
43. Uchino M, Uyama E, Kawano H, Hokamaki J, Kugiyama K, Murakami Y, et al. A
histochemical and electron microscopic study of skeletal and cardiac muscle
from a Fabry disease patient and carrier. Acta Neuropathol. 1995;90(3):334–8.
44. Mehta A, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, et al.
Therapeutic goals in the treatment of Fabry disease. Genet Med.
2010;12(11):713–20.
